top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
The Maudsley prescribing guidelines in psychiatry [[electronic resource] /] / David Taylor, Carol Paton, Shitij Kapur
The Maudsley prescribing guidelines in psychiatry [[electronic resource] /] / David Taylor, Carol Paton, Shitij Kapur
Autore Taylor David <1963-, >
Edizione [11th edition.]
Pubbl/distr/stampa Chichester, West Sussex, : John Wiley & Sons, 2012
Descrizione fisica 1 online resource (682 p.)
Disciplina 616.89/18
Altri autori (Persone) PatonCarol
KapurShitij
TaylorDavid <1946->
Soggetto topico Psychopharmacology - Great Britain
Psychotropic drugs - Great Britain
Soggetto genere / forma Electronic books.
ISBN 1-118-32325-4
0-470-97968-2
1-283-49701-8
9786613497017
0-470-97969-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto The Maudsley Prescribing Guidelines in Psychiatry; Contents; Preface; Acknowledgements; Notes on using The Maudsley Prescribing Guidelines; Notes on inclusion of drugs; List of abbreviations; Chapter 1 Plasma level monitoring of psychotropic drugs and anticonvulsants; Interpreting sample results; Chapter 2 Schizophrenia; Antipsychotic drugs; Antipsychotic drugs: equivalent doses; Antipsychotic drugs: minimum effective doses; Antipsychotic drugs: licensed maximum doses; New antipsychotic drugs; Antipsychotic drugs: general principles of prescribing
National Institute for Health and Clinical Excellence guidelines for the treatment of schizophrenia Treatment algorithms for schizophrenia; Antipsychotic drugs: monitoring of metabolic effects; Switching antipsychotic drugs because of poor tolerability; Antipsychotic response: to increase the dose, to switch, to add or just wait - what is the right move?; Speed and onset of antipsychotic drug action; First-generation antipsychotic drugs: place in therapy; Antipsychotic drugs: long-acting injections; Risperidone long-acting injection; Paliperidone palmitate long-acting injection
Management of patients on long-term depots: dose reduction Combined antipsychotic drugs; High-dose antipsychotic drugs: prescribing and monitoring; Negative symptoms in schizophrenia; Antipsychotic prophylaxis; Refractory schizophrenia and clozapine; Clozapine augmentation; Refractory schizophrenia: alternatives to clozapine; Clozapine: management of common adverse effects; Clozapine: uncommon or unusual adverse effects; Clozapine: serious haematological and cardiovascular adverse effects; Clozapine, neutropenia and lithium; Clozapine and chemotherapy; Clozapine-related hypersalivation
Guidelines for the initiation of clozapine for patients based in the community Omega-3 fatty acids (fish oils) in schizophrenia; Extrapyramidal side-effects of antipsychotic drug treatment; Treatment of antipsychotic-induced akathisia; Treatment of tardive dyskinesia; Neuroleptic malignant syndrome; Catatonia; Cardiovascular effects of antipsychotic drug treatment; Antipsychotic drugs and hypertension; Hyperprolactinaemia; Antipsychotic-induced weight gain; Treatment of drug-induced weight gain; Antipsychotic drugs, diabetes and impaired glucose tolerance; Antipsychotic drugs and dyslipidaemia
Antipsychotic drugs and sexual dysfunction Antipsychotic-associated hyponatraemia; Antipsychotics and pneumonia; Relative adverse effects of antipsychotic drugs: a rough guide; Chapter 3 Bipolar disorder; Valproate; Lithium; Carbamazepine; Physical monitoring of people with bipolar disorder; Treatment of acute mania or hypomania; Antipsychotic drugs in bipolar disorder; Bipolar depression; Rapid cycling bipolar disorder; Prophylaxis in bipolar disorder; Chapter 4 Depression and anxiety; Depression; Antidepressants; Treatment of resistant depression; Treatment of psychotic depression
Electroconvulsive therapy and psychotropic drugs
Record Nr. UNINA-9910457931603321
Taylor David <1963-, >  
Chichester, West Sussex, : John Wiley & Sons, 2012
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The Maudsley prescribing guidelines in psychiatry [[electronic resource] /] / David Taylor, Carol Paton, Shitij Kapur
The Maudsley prescribing guidelines in psychiatry [[electronic resource] /] / David Taylor, Carol Paton, Shitij Kapur
Autore Taylor David <1963-, >
Edizione [11th edition.]
Pubbl/distr/stampa Chichester, West Sussex, : John Wiley & Sons, 2012
Descrizione fisica 1 online resource (682 p.)
Disciplina 616.89/18
Altri autori (Persone) PatonCarol
KapurShitij
TaylorDavid <1946->
Soggetto topico Psychopharmacology - Great Britain
Psychotropic drugs - Great Britain
ISBN 1-118-32325-4
0-470-97968-2
1-283-49701-8
9786613497017
0-470-97969-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto The Maudsley Prescribing Guidelines in Psychiatry; Contents; Preface; Acknowledgements; Notes on using The Maudsley Prescribing Guidelines; Notes on inclusion of drugs; List of abbreviations; Chapter 1 Plasma level monitoring of psychotropic drugs and anticonvulsants; Interpreting sample results; Chapter 2 Schizophrenia; Antipsychotic drugs; Antipsychotic drugs: equivalent doses; Antipsychotic drugs: minimum effective doses; Antipsychotic drugs: licensed maximum doses; New antipsychotic drugs; Antipsychotic drugs: general principles of prescribing
National Institute for Health and Clinical Excellence guidelines for the treatment of schizophrenia Treatment algorithms for schizophrenia; Antipsychotic drugs: monitoring of metabolic effects; Switching antipsychotic drugs because of poor tolerability; Antipsychotic response: to increase the dose, to switch, to add or just wait - what is the right move?; Speed and onset of antipsychotic drug action; First-generation antipsychotic drugs: place in therapy; Antipsychotic drugs: long-acting injections; Risperidone long-acting injection; Paliperidone palmitate long-acting injection
Management of patients on long-term depots: dose reduction Combined antipsychotic drugs; High-dose antipsychotic drugs: prescribing and monitoring; Negative symptoms in schizophrenia; Antipsychotic prophylaxis; Refractory schizophrenia and clozapine; Clozapine augmentation; Refractory schizophrenia: alternatives to clozapine; Clozapine: management of common adverse effects; Clozapine: uncommon or unusual adverse effects; Clozapine: serious haematological and cardiovascular adverse effects; Clozapine, neutropenia and lithium; Clozapine and chemotherapy; Clozapine-related hypersalivation
Guidelines for the initiation of clozapine for patients based in the community Omega-3 fatty acids (fish oils) in schizophrenia; Extrapyramidal side-effects of antipsychotic drug treatment; Treatment of antipsychotic-induced akathisia; Treatment of tardive dyskinesia; Neuroleptic malignant syndrome; Catatonia; Cardiovascular effects of antipsychotic drug treatment; Antipsychotic drugs and hypertension; Hyperprolactinaemia; Antipsychotic-induced weight gain; Treatment of drug-induced weight gain; Antipsychotic drugs, diabetes and impaired glucose tolerance; Antipsychotic drugs and dyslipidaemia
Antipsychotic drugs and sexual dysfunction Antipsychotic-associated hyponatraemia; Antipsychotics and pneumonia; Relative adverse effects of antipsychotic drugs: a rough guide; Chapter 3 Bipolar disorder; Valproate; Lithium; Carbamazepine; Physical monitoring of people with bipolar disorder; Treatment of acute mania or hypomania; Antipsychotic drugs in bipolar disorder; Bipolar depression; Rapid cycling bipolar disorder; Prophylaxis in bipolar disorder; Chapter 4 Depression and anxiety; Depression; Antidepressants; Treatment of resistant depression; Treatment of psychotic depression
Electroconvulsive therapy and psychotropic drugs
Record Nr. UNINA-9910779093803321
Taylor David <1963-, >  
Chichester, West Sussex, : John Wiley & Sons, 2012
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
The Maudsley prescribing guidelines in psychiatry / / David Taylor, Carol Paton, Shitij Kapur
The Maudsley prescribing guidelines in psychiatry / / David Taylor, Carol Paton, Shitij Kapur
Autore Taylor David <1963-, >
Edizione [11th edition.]
Pubbl/distr/stampa Chichester, West Sussex, : John Wiley & Sons, 2012
Descrizione fisica 1 online resource (682 p.)
Disciplina 616.89/18
Altri autori (Persone) PatonCarol
KapurShitij
TaylorDavid <1946->
Soggetto topico Psychopharmacology - Great Britain
Psychotropic drugs - Great Britain
ISBN 1-118-32325-4
0-470-97968-2
1-283-49701-8
9786613497017
0-470-97969-0
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto The Maudsley Prescribing Guidelines in Psychiatry; Contents; Preface; Acknowledgements; Notes on using The Maudsley Prescribing Guidelines; Notes on inclusion of drugs; List of abbreviations; Chapter 1 Plasma level monitoring of psychotropic drugs and anticonvulsants; Interpreting sample results; Chapter 2 Schizophrenia; Antipsychotic drugs; Antipsychotic drugs: equivalent doses; Antipsychotic drugs: minimum effective doses; Antipsychotic drugs: licensed maximum doses; New antipsychotic drugs; Antipsychotic drugs: general principles of prescribing
National Institute for Health and Clinical Excellence guidelines for the treatment of schizophrenia Treatment algorithms for schizophrenia; Antipsychotic drugs: monitoring of metabolic effects; Switching antipsychotic drugs because of poor tolerability; Antipsychotic response: to increase the dose, to switch, to add or just wait - what is the right move?; Speed and onset of antipsychotic drug action; First-generation antipsychotic drugs: place in therapy; Antipsychotic drugs: long-acting injections; Risperidone long-acting injection; Paliperidone palmitate long-acting injection
Management of patients on long-term depots: dose reduction Combined antipsychotic drugs; High-dose antipsychotic drugs: prescribing and monitoring; Negative symptoms in schizophrenia; Antipsychotic prophylaxis; Refractory schizophrenia and clozapine; Clozapine augmentation; Refractory schizophrenia: alternatives to clozapine; Clozapine: management of common adverse effects; Clozapine: uncommon or unusual adverse effects; Clozapine: serious haematological and cardiovascular adverse effects; Clozapine, neutropenia and lithium; Clozapine and chemotherapy; Clozapine-related hypersalivation
Guidelines for the initiation of clozapine for patients based in the community Omega-3 fatty acids (fish oils) in schizophrenia; Extrapyramidal side-effects of antipsychotic drug treatment; Treatment of antipsychotic-induced akathisia; Treatment of tardive dyskinesia; Neuroleptic malignant syndrome; Catatonia; Cardiovascular effects of antipsychotic drug treatment; Antipsychotic drugs and hypertension; Hyperprolactinaemia; Antipsychotic-induced weight gain; Treatment of drug-induced weight gain; Antipsychotic drugs, diabetes and impaired glucose tolerance; Antipsychotic drugs and dyslipidaemia
Antipsychotic drugs and sexual dysfunction Antipsychotic-associated hyponatraemia; Antipsychotics and pneumonia; Relative adverse effects of antipsychotic drugs: a rough guide; Chapter 3 Bipolar disorder; Valproate; Lithium; Carbamazepine; Physical monitoring of people with bipolar disorder; Treatment of acute mania or hypomania; Antipsychotic drugs in bipolar disorder; Bipolar depression; Rapid cycling bipolar disorder; Prophylaxis in bipolar disorder; Chapter 4 Depression and anxiety; Depression; Antidepressants; Treatment of resistant depression; Treatment of psychotic depression
Electroconvulsive therapy and psychotropic drugs
Record Nr. UNINA-9910810223003321
Taylor David <1963-, >  
Chichester, West Sussex, : John Wiley & Sons, 2012
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui